Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash & Current Investments (2016 - 2025)

Neurocrine Biosciences' Cash & Current Investments history spans 16 years, with the latest figure at $1.5 billion for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 37.57% year-over-year to $1.5 billion; the TTM value through Dec 2025 reached $1.5 billion, up 37.57%, while the annual FY2025 figure was $1.5 billion, 37.57% up from the prior year.
  • Cash & Current Investments reached $1.5 billion in Q4 2025 per NBIX's latest filing, up from $1.1 billion in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $1.5 billion in Q4 2025 to a low of $648.3 million in Q2 2022.
  • Average Cash & Current Investments over 5 years is $971.1 million, with a median of $976.2 million recorded in 2023.
  • Peak YoY movement for Cash & Current Investments: fell 26.74% in 2022, then soared 50.66% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $714.5 million in 2021, then surged by 39.55% to $997.1 million in 2022, then increased by 4.26% to $1.0 billion in 2023, then increased by 3.51% to $1.1 billion in 2024, then skyrocketed by 37.57% to $1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Cash & Current Investments are $1.5 billion (Q4 2025), $1.1 billion (Q3 2025), and $975.6 million (Q2 2025).